These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 35484651)
21. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. Gambacorti-Passerini C; Piazza R JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011 [No Abstract] [Full Text] [Related]
22. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India. Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669 [No Abstract] [Full Text] [Related]
23. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells. Wang XY; Sun GB; Wang YJ; Yan F Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163 [TBL] [Abstract][Full Text] [Related]
24. [Mechanisms of resistance to BCR-ABL kinase inhibitors]. Diamond J; da Silva MG Acta Med Port; 2013; 26(4):402-8. PubMed ID: 24016650 [TBL] [Abstract][Full Text] [Related]
25. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia. Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336 [TBL] [Abstract][Full Text] [Related]
27. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Nteliopoulos G; Bazeos A; Claudiani S; Gerrard G; Curry E; Szydlo R; Alikian M; Foong HE; Nikolakopoulou Z; Loaiza S; Khorashad JS; Milojkovic D; Perrotti D; Gale RP; Foroni L; Apperley JF Haematologica; 2019 Dec; 104(12):2400-2409. PubMed ID: 31073075 [TBL] [Abstract][Full Text] [Related]
28. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012 [TBL] [Abstract][Full Text] [Related]
29. [Response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia]. Ibarra-Hernández A; Sosa-Quintero LS; Garcés-Ruiz OM; Aguilar-López LB; Rubio-Jurado B; Vega-Ruiz A Rev Med Inst Mex Seguro Soc; 2014; 52(3):266-9. PubMed ID: 24878084 [TBL] [Abstract][Full Text] [Related]
30. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China. Cai Y; Liu C; Guo Y; Chen X; Zhang L; Chen Y; Zou Y; Yang W; Zhu X Int J Hematol; 2021 Mar; 113(3):413-421. PubMed ID: 33386594 [TBL] [Abstract][Full Text] [Related]
31. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334 [TBL] [Abstract][Full Text] [Related]
32. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F; Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665 [TBL] [Abstract][Full Text] [Related]
33. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722 [TBL] [Abstract][Full Text] [Related]
34. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118 [TBL] [Abstract][Full Text] [Related]
35. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884 [TBL] [Abstract][Full Text] [Related]
36. New tyrosine kinase inhibitors in chronic myeloid leukemia. Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950 [TBL] [Abstract][Full Text] [Related]